Monopar Therapeutics Inc. (MNPR)

NASDAQ | Biotech | Biotech / Drug Development
Free
No email, no account, no signup.
Pulling latest news for Monopar Therapeutics Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biotech / Drug Development
Market Cap
$380M
We're already tracking Monopar Therapeutics Inc. — here are the latest events we've registered

Recent News

  • In March 2026, Monopar announced plans to submit a New Drug Application (NDA) for ALXN1840 in mid-2026 following positive interactions with the FDA regarding its Wilson disease program. The company also presented Phase 3 efficacy and safety data for the candidate at the American Academy of Neurology 2026 Annual Meeting.
Want to know how this news affects Monopar Therapeutics Inc.? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Monopar Therapeutics Inc. will be delivered in the same format.
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
Monopar Therapeutics Inc. (MNPR)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.